SCHEMBL806464

SCHEMBL806464

CC[C@H](C)Cc1cc(C)ccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 1/20 0.50
GABRA1 P14867 1/20 0.46
GABRB2 P47870 1/20 0.46
TRPA1 O75762 2/20 0.43
TP53 P04637 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTT P42858 1/20 0.41
LMNA P02545 3/20 0.41
CHRM1 P11229 1/20 0.41
SLC6A2 P23975 1/20 0.41
ADRA1A P35348 1/20 0.41
HTR2B P41595 1/20 0.41
ALOX15 P16050 3/20 0.39
HSD17B10 Q99714 2/20 0.39
ALDH1A1 P00352 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HPGD P15428 2/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23153076 1.00 AMY1A (0.50) AMY1AGABRA1GABRB2TRPA1TP53
SCHEMBL3960601 0.82 GABRA1 (0.66) AMY1AGABRA1GABRB2TRPA1TP53
SCHEMBL5159444 0.81 GABRA1 (0.65) GABRA1GABRB2TRPA1TP53TDP1
SCHEMBL15666913 0.81 AMY1A (0.53) AMY1AGABRA1GABRB2TRPA1TP53
SCHEMBL15666912 0.81 AMY1A (0.53) AMY1AGABRA1GABRB2TRPA1TP53
SCHEMBL23049820 0.81 NR3C1 (0.48) TDP1HTTALDH1A1HPGDGAA
SCHEMBL15667381 0.81 AMY1A (0.53) AMY1AGABRA1GABRB2TRPA1TP53
SCHEMBL14478234 0.79 AMY1A (0.52) AMY1AGABRA1GABRB2TRPA1TP53
SCHEMBL5271763 0.78 AMY1A (0.41) AMY1AGABRA1GABRB2TRPA1TP53
SCHEMBL17500128 0.77 CYP2D6 (0.54) GABRA1GABRB2TDP1ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012036253-A1 HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-03-22 WO disclosed